Finance

Lists
Why is HLN up 2,54%?
Dive Deeper
HLN:NYSE
Haleon PLC - ADR
USD 9,68
+2,54%
(+0,24) 1D
USD 9,70
+0,21% (+0,020)
After hours
Closed: 14 Okt., 16:00:03 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HLN...
Open
USD 9,53
High
USD 9,70
Low
USD 9,49
Mkt. cap
42,30 mjd
Avg. vol.
19,48 m
Volume
13,84 m
Dividend
2,05%
Quarterly dividend
USD 0,05
Ex-dividend date
13 Aug. 2026
P/E ratio
20,15
52-wk high
USD 11,28
52-wk low
USD 8,65
EPS
USD 0,48
Beta
0,16
Shares outstanding
4,40 mjd
No. of employees
25 k
Open
USD 9,53
High
USD 9,70
Low
USD 9,49
Mkt. cap
42,30 mjd
Avg. vol.
19,48 m
Volume
13,84 m
Dividend
2,05%
Quarterly dividend
USD 0,05
Ex-dividend date
13 Aug. 2026
P/E ratio
20,15
52-wk high
USD 11,28
52-wk low
USD 8,65
EPS
USD 0,48
Beta
0,16
Shares outstanding
4,40 mjd
No. of employees
25 k
News stories
From web sources and news partners
Profile
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022. Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Wikipedia
About Haleon PLC - ADR
CEO-
Employees24,5 k
Founded18 Jul. 2022
Headquarters-
SectorPharmaceutical industry
Websitehaleon.com
Analyst ratings
Based on 2 analysts giving stock ratings to HLN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for HLN in the last 3 months.
Highest
Current USD 9,68
USD 12,40 (+28,10%)
Average
USD 11,70 (+20,87%)
Lowest
USD 11,00 (+13,64%)
Analyst
Recommendation
Action
Price target
Projected
Date
Taylor Conrad
Argus Research
Buy
Maintained
USD 11,00
+13,6%
08/10/2026
Unknown Analyst
Morgan Stanley
Buy
Maintained
USD 12,40
+28,1%
08/06/2026
Unknown Analyst
Berenberg Bank
Buy
Reiterated
USD 13,92
+43,8%
03/16/2026
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,78 mjd
2,78 mjd
2,80 mjd
2,80 mjd
Cost of goods sold
970,50 m
970,50 m
949,50 m
949,50 m
Cost of revenue
970,50 m
970,50 m
949,50 m
949,50 m
Research and development expenses
81,50 m
81,50 m
73,50 m
73,50 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,08 mjd
1,08 mjd
1,11 mjd
1,11 mjd
Operating expense
1,16 mjd
1,16 mjd
1,18 mjd
1,18 mjd
Total operating expenses
2,13 mjd
2,13 mjd
2,13 mjd
2,13 mjd
Operating income
643,00 m
643,00 m
670,50 m
670,50 m
Other non operating income
-10,50 m
-10,50 m
1,50 m
1,50 m
EBT including unusual items
538,50 m
538,50 m
528,00 m
528,00 m
EBT excluding unusual items
552,00 m
552,00 m
612,50 m
612,50 m
Income tax expense
105,00 m
105,00 m
143,00 m
143,00 m
Effective tax rate
19,50%
19,50%
27,08%
27,08%
Other operating expenses
-
-
-
-
Net income
430,50 m
430,50 m
381,00 m
381,00 m
Net profit margin
15,51%
15,51%
13,60%
13,60%
Earnings per share
-
-
-
-
Interest and investment income
5,00 m
5,00 m
17,00 m
17,00 m
Interest expense
-85,50 m
-85,50 m
-76,50 m
-76,50 m
Net interest expenses
-80,50 m
-80,50 m
-59,50 m
-59,50 m
Depreciation and amortization charges
-
-
-
-
EBITDA
704,50 m
704,50 m
724,00 m
724,00 m
Gain or loss from assets sale
-
-
-10,00 m
-10,00 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme